{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/gynaecological-cancers-recognition-referral/diagnosis/symptoms-suggestive-of-gynaecological-cancers/","result":{"pageContext":{"chapter":{"id":"8a44798e-bc7c-5377-9f3c-b743ee5a7af7","slug":"symptoms-suggestive-of-gynaecological-cancers","fullItemName":"Symptoms suggestive of gynaecological cancers","depth":2,"htmlHeader":"<!-- begin field a73f389b-7912-4733-92f1-c7be596fb5e7 --><h2>Symptoms suggestive of gynaecological cancers</h2><!-- end field a73f389b-7912-4733-92f1-c7be596fb5e7 -->","summary":"","htmlStringContent":"<!-- begin item e4dd75d0-298a-4bb7-848d-83de5c6c0e7c --><!-- begin field aede48a8-fb5a-498f-9dfa-5e1a2e9f386b --><p><strong>Table 2.</strong> Symptoms suggestive of gynaecological cancers.</p><table data-table-id=\"3fb29d0b-e997-475b-8397-acce014f3ecf\"><thead><tr><th>Symptom</th><th>Possible cancer</th><th>Referral recommendation</th></tr></thead><tbody><tr><td>Appearance of cervix consistent with cervical cancer</td><td>Cervical</td><td>Consider a suspected cancer pathway referral (for an appointment within 2 weeks)</td></tr><tr><td>Blood glucose levels high with visible haematuria in women age 55 years and over</td><td>Endometrial</td><td>Consider a direct access ultrasound scan</td></tr><tr><td>Haemoglobin levels low with visible haematuria in women age 55 years and over</td><td>Endometrial</td><td>Consider a direct access ultrasound scan</td></tr><tr><td>Haematuria (visible) with low haemoglobin levels or thrombocytosis or high blood glucose levels or unexplained vaginal discharge in women age 55 years and over</td><td>Endometrial</td><td>Consider a direct access ultrasound scan</td></tr><tr><td>Post-menopausal bleeding in women age 55 years and over (unexplained vaginal bleeding more than 12 months after menstruation has stopped because of the menopause)</td><td>Endometrial</td><td>Refer women using a suspected cancer pathway referral (for an appointment within 2 weeks)</td></tr><tr><td>Post-menopausal bleeding in women age under 55 years (unexplained vaginal bleeding more than 12 months after menstruation has stopped because of the menopause)</td><td>Endometrial</td><td>Consider a suspected cancer pathway referral (for an appointment within 2 weeks)</td></tr><tr><td>Thrombocytosis with visible haematuria or vaginal discharge (unexplained) in women age 55 years and over</td><td>Endometrial</td><td>Consider a direct access ultrasound scan</td></tr><tr><td>Vaginal discharge (unexplained) either at first presentation or with thrombocytosis or with haematuria, in women age 55 years and over</td><td>Endometrial</td><td>Consider a direct access ultrasound scan</td></tr><tr><td>Appetite loss or early satiety (persistent or frequent – particularly more than 12 times per month) in women, especially if age 50 years and over</td><td>Ovarian</td><td><p>Carry out appropriate investigatons<sup>*</sup></p><p>Measure serum CA125<sup>*</sup></p></td></tr><tr><td>Abdominal distension (persistent or frequent – particularly more than 12 times per month) in women, especially if age 50 years and over</td><td>Ovarian</td><td><p>Carry out appropriate investigations<sup>*</sup></p><p>Measure serum CA125<sup>*</sup></p></td></tr><tr><td>Ascites and/or a pelvic or abdominal mass identified by physical examination (which is not obviously uterine fibroids) in women</td><td>Ovarian</td><td>Refer urgently<sup>*</sup> (within 2 weeks)</td></tr><tr><td>Abdominal or pelvic mass identified by physical examination (which is not obviously uterine fibroids) in women</td><td>Ovarian</td><td>Refer urgently<sup>*</sup> (within 2 weeks)</td></tr><tr><td>Abdominal or pelvic pain (persistent or frequent – particularly more than 12 times per month) in women, especially if age 50 years and over</td><td>Ovarian</td><td><p>Carry out appropriate investigations<sup>*</sup></p><p>Measure serum CA125<sup>*</sup></p></td></tr><tr><td>Irritable bowel syndrome symptoms within the last 12 months in women age 50 years and over</td><td>Ovarian</td><td><p>Carry out appropriate tests for ovarian cancer, because irritable bowel syndrome rarely presents for the first time in women of this age<sup>*</sup></p><p>Measure serum CA125<sup>*</sup></p></td></tr><tr><td>Change in bowel habit (unexplained) in women</td><td>Ovarian</td><td><p>Consider carrying out appropriate investigations<sup>*</sup></p><p>Measure serum CA125<sup>*</sup></p></td></tr><tr><td>Fatigue (unexplained) in women</td><td>Ovarian</td><td><p>Carry out appropriate investigations<sup>*</sup></p><p>Measure serum CA125<sup>*</sup></p></td></tr><tr><td>Urinary urgency and/or frequency (increased and persistent or frequent – particularly more than 12 times per month) in women, especially if age 50 years and over</td><td>Ovarian</td><td><p>Carry out tests in primary care<sup>*</sup></p><p>Measure serum CA125 in primary care<sup>*</sup></p></td></tr><tr><td>Weight loss (unexplained) in women</td><td>Ovarian</td><td><p>Consider carrying out tests in primary care<sup>*</sup></p><p>Measure serum CA125 in primary care<sup>*</sup></p></td></tr><tr><td>Serum CA125 results</td><td>Ovarian</td><td><p>If serum CA125 is 35 IU/ml or greater, arrange an ultrasound scan of the abdomen and pelvis<sup>*</sup></p><p>Normal serum CA125 (less than 35 IU/ml), or CA125 of 35 IU/ml or greater but a normal ultrasound: assess carefully for other clinical causes of her symptoms and investigate if appropriate. If no other clinical cause is apparent, advise her to return if symptoms become more frequent and/or persistent<sup>*</sup></p></td></tr><tr><td>Ultrasound suggests ovarian cancer</td><td>Ovarian</td><td><p>Refer urgently for further investigation<sup>*</sup></p></td></tr><tr><td>Ultrasound normal with CA125 of 35 IU/ml or greater</td><td>Ovarian</td><td><p>Assess carefully for other clinical causes if symptoms and investigate if appropriate<sup>*</sup></p><p>If no other clinical cause is apparent, advise to return if symptoms become more frequent and/or persistent<sup>*</sup></p></td></tr><tr><td>Vaginal mass (unexplained and palpable) in or at the entrance to the vagina</td><td>Vaginal</td><td>Consider a suspected cancer pathway referral (for an appointment within 2 weeks)</td></tr><tr><td>Vulval bleeding (unexplained) in women</td><td>Vulval</td><td>Consider a suspected cancer pathway referral (for an appointment within 2 weeks)</td></tr><tr><td>Vulval lump or ulceration (unexplained)</td><td>Vulval</td><td>Consider a suspected cancer pathway referral (for an appointment within 2 weeks)</td></tr><tr><td colspan=\"3\"><sup>* </sup>The recommendations for ovarian cancer apply to women aged 18 years and over</td></tr><tr><td colspan=\"3\"><strong>Data from:</strong> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gynaecological-cancers-recognition-referral/references/\">NICE, 2015</a>]</td></tr></tbody></table><!-- end field aede48a8-fb5a-498f-9dfa-5e1a2e9f386b --><!-- end item e4dd75d0-298a-4bb7-848d-83de5c6c0e7c -->","topic":{"id":"ee6103b8-1f49-5865-acd7-5a9d20d194e6","topicId":"e261ffa1-7f7e-430a-9e12-c985aaca7f4d","topicName":"Gynaecological cancers - recognition and referral","slug":"gynaecological-cancers-recognition-referral","lastRevised":"Last revised in February 2021","chapters":[{"id":"65e105c6-5f7b-59ad-9801-824c409f981c","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"e401d47d-3905-5eda-b3cd-1b4eef408bdf","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"e31afef3-1c88-506d-ad84-0a6b30b9dba1","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"278052bd-be26-5c26-84bc-2113aee7dc30","slug":"changes","fullItemName":"Changes"},{"id":"efc1c0f8-bdb1-5114-97b1-648a6a52a459","slug":"update","fullItemName":"Update"}]},{"id":"e8e62e95-f70c-5b2b-9b10-0c9c5f2e9c95","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"f85ffb79-0957-5932-821c-906cec331a84","slug":"goals","fullItemName":"Goals"},{"id":"7d1d0b80-0602-5d4c-98eb-6a49f27689c0","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"9244c05b-86d8-5f85-b189-5479cde68eeb","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"b605e7ea-7a24-5403-96d0-e0fac5a89219","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"703f3f20-548e-5808-a218-c091ab3b216f","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"f4beaa7f-d7cd-576b-8692-c4516abd0c56","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"e14ce3a1-8460-551b-a361-43faa360c514","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"47f1f404-6941-5185-bcab-0175066bad01","slug":"presentation","fullItemName":"Presentation"},{"id":"a9c43384-a7d0-51f4-8d73-6b71541884df","slug":"prevalence","fullItemName":"Prevalence"},{"id":"044108ce-710b-5ec8-a3ae-429b107039bf","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"9da77476-bb29-59ac-a917-0d3da982f80f","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"8a44798e-bc7c-5377-9f3c-b743ee5a7af7","slug":"symptoms-suggestive-of-gynaecological-cancers","fullItemName":"Symptoms suggestive of gynaecological cancers"}]},{"id":"b5a02174-cd66-5e92-9819-0302058cf230","fullItemName":"Management","slug":"management","subChapters":[{"id":"415eae91-f38a-5ccc-95f0-68d5ca386095","slug":"referral-for-suspected-gynaecological-cancer","fullItemName":"Scenario: Referral for suspected gynaecological cancer"}]},{"id":"8f87e182-3ee3-55c3-b6ff-ee2773b11083","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"7030c633-3342-56a4-872a-5d01b1950d05","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"3e4a0622-59ba-59f1-a249-25f37835db8f","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"598e9e20-db1b-5bd6-bad9-da74dd559795","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"d01e7124-01f5-52fc-a22b-2f245daf8632","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"e5593853-81b8-58eb-a621-1e437e26ef58","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"06edaae5-710d-5a2f-8d9f-e20e29be3d6e","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"4aae08c9-f011-5561-8ca0-183457de55ec","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"9da77476-bb29-59ac-a917-0d3da982f80f","slug":"diagnosis","fullItemName":"Diagnosis"},"subChapters":[{"id":"bc7a02b3-bcbf-5997-b1b7-91deaf85a51d","slug":"basis-for-recommendation-13a","fullItemName":"Basis for recommendation","depth":3,"htmlHeader":"<!-- begin field 3db043bf-5ed2-4f15-9a71-4702a922a47e --><h3>Basis for recommendation</h3><!-- end field 3db043bf-5ed2-4f15-9a71-4702a922a47e -->","summary":null,"htmlStringContent":"<!-- begin item 13ae6f8b-57fc-4927-bcd0-9b99e2f5c8ea --><!-- begin field b3bcf6f1-82f5-4533-939d-44801e0766ec --><p>This is a direct implementation of the National Institute for Health and Care Excellence guideline <em>Suspected cancer: recognition and r</em><em>eferral</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gynaecological-cancers-recognition-referral/references/\">NICE, 2015</a>].</p><!-- end field b3bcf6f1-82f5-4533-939d-44801e0766ec --><!-- end item 13ae6f8b-57fc-4927-bcd0-9b99e2f5c8ea -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}